Study of ADARx Treatment for Kidney Disease in Chinese Adults
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney disease confirmed by a kidney biopsy (IgAN, C3G, or IC-MPGN)
- Your kidney function (eGFR) is at least 30 mL/min/1.73m² (moderate to mild kidney disease)
- You have not had a kidney transplant or other major organ transplant
- You have not needed dialysis or other kidney replacement therapy for more than 3 days
- You are willing to receive required vaccinations
- You do not have active tuberculosis, HIV, or other serious ongoing infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
This study tests an experimental drug called SGB-9768 for people with certain kidney diseases that involve complement protein deposits. The goal is to see if it can reduce kidney damage and protein loss in urine.
This trial tests whether a new investigational drug called ARGX-121 can reduce protein in the urine of people with IgA nephropathy (IgAN), a kidney disease. It may help slow the loss of kidney function.
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
This study tests a new medicine, RG002C0106, to see how it is processed in people with normal or mildly to moderately reduced kidney function. It helps researchers understand how kidney function affects the drug, which is important for future dosing recommendations.
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
Hear when a new Immunoglobulin A Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.